{"id":"humulin-insulin-mixtard","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mixtard contains a mixture of soluble (rapid-acting) insulin and isophane (intermediate-acting) insulin, allowing for both immediate postprandial glucose control and sustained basal coverage. The insulin binds to insulin receptors on muscle, fat, and liver cells, promoting glucose uptake and storage while inhibiting hepatic glucose production. This dual-action formulation provides convenient once or twice-daily dosing for diabetes management.","oneSentence":"Humulin Insulin Mixtard is a fixed combination of rapid-acting and intermediate-acting insulin that replaces or supplements endogenous insulin to regulate blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:30.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06855615","phase":"PHASE4","title":"Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hospital Sultanah Aminah Johor Bahru","startDate":"2020-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":44},{"nctId":"NCT03106870","phase":"NA","title":"Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2016-06","conditions":"Gestational Diabetes Mellitus in Pregnancy","enrollment":62},{"nctId":"NCT01492218","phase":"","title":"Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-03-15","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1330},{"nctId":"NCT01467401","phase":"PHASE4","title":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT01536626","phase":"","title":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":211},{"nctId":"NCT00657319","phase":"","title":"Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":3495},{"nctId":"NCT01697618","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1997-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":13},{"nctId":"NCT01492166","phase":"","title":"Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1935},{"nctId":"NCT02138006","phase":"NA","title":"Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"1982-09","conditions":"Coronary Heart Disease, Stroke, Renal Failure","enrollment":102},{"nctId":"NCT01486888","phase":"PHASE1","title":"Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Healthy","enrollment":45},{"nctId":"NCT02333851","phase":"PHASE4","title":"Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)","status":"TERMINATED","sponsor":"Hospital Universitario Central de Asturias","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus","enrollment":72},{"nctId":"NCT01915550","phase":"PHASE3","title":"Metformin as Adjuvant to Insulin Therapy in Insulin-resistant Diabetes Mellitus With Pregnancy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2012-04","conditions":"Diabetes Mellitus","enrollment":90},{"nctId":"NCT01143948","phase":"PHASE4","title":"Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2011-01","conditions":"Type 2 Diabetes, Liver Cirrhosis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Humulin Insulin Mixtard","genericName":"Humulin Insulin Mixtard","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Humulin Insulin Mixtard is a fixed combination of rapid-acting and intermediate-acting insulin that replaces or supplements endogenous insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}